Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Vinay Prasad is tightening the screws at the FDA, overruling staff and signaling a tougher stance on vaccines and gene therapies — which, as Adam Feuerstein points out, is consistent with his historic skepticism of surrogate endpoints and trial design.
At the same time, BridgeBio is stacking Phase 3 wins and European investors are organizing to keep their biotechs — and IPOs — within the E.U.Continue to STAT+ to read the full story…